Fox Chase Cancer Center News

Omega-3 Fatty Acids More Effective at Inhibiting Growth of Triple-Negative Breast Cancer than of Luminal Breast Cancers

WASHINGTON, DC (April 9, 2013)—Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively than cells from luminal types of the disease. The omega-3s worked against all types of cancerous cells, but the effect was observed to be stronger in triple-negative cell lines, reducing proliferation by as much as 90 percent. The findings will be presented at the AACR Annual Meeting 2013 on Tuesday, April 9.

VIEW STORY

New Technology Spots Drugs' Early Impact on Cancer

WASHINGTON, DC (April 9, 2013)—A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, according to new findings presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013 on Tuesday, April 9.

VIEW STORY

Fox Chase Cancer Center Researchers Identify Critical Metabolic Alterations in Triple-Negative Breast Cancer Cells

WASHINGTON, DC (April 9, 2013)—Researchers at Fox Chase Cancer Center have identified a host of small molecules critical to metabolism in cells of triple-negative breast cancer—one of the least understood groups of breast cancer. These molecules, called metabolites, include key players in energy regulation and lipid synthesis. They could help pave the way for helping researchers differentiate among different forms of the disease and ultimately point to new targets for treatment.

VIEW STORY

Exploring lincRNA's Role in Breast Cancer

WASHINGTON, DC (April 8, 2013)—Once considered part of the “junk” of our genome, much of the DNA between protein-coding genes is now known to be transcribed. New findings by scientists at Fox Chase Cancer Center have identified several dozen transcripts known as lincRNAs, or long intergenic non-coding RNAs, that are dysregulated in breast cancer.

VIEW STORY

Fox Chase Researchers Reveal that Different Drug Combinations Work Best for Prevention Versus Treatment of Colorectal Tumors

WASHINGTON, DC (April 7, 2013)—Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Once colorectal cancer has spread to other parts of the body, only 11 percent of patients will survive five years from the date of their diagnosis. Most colorectal cancers are adenocarcinomas—cancers that begin in cells that make and release mucus and other fluids. Adenocarcinomas begin as benign tumors called adenomas, which become malignant over time. By treating adenomas before they become cancerous, it could be possible to prevent colorectal cancer.

VIEW STORY

Current HPV Vaccine May Not Help Some Women with Immune Problems

WASHINGTON, DC (April 7, 2013)—Women with HIV acquire cancer-causing forms of the human papillomavirus (HPV) that are not included in the current HPV vaccines Gardasil and Cervarix, according to new research from Fox Chase Cancer Center being presented at the AACR Annual Meeting 2013 on Sunday, April 7.

"People with issues in their immune system such as HIV will be at risk of acquiring HPV, as well – and the current vaccine may not fully protect them," says study author Elizabeth Blackman, MPH, research specialist at Fox Chase.

VIEW STORY

Fox Chase Cancer Center Health Careers Symposium Kicks Off Re-Designed High School Program

PHILADELPHIA, PA (March 21, 2013)—Fox Chase Cancer Center will be hosting a  one-day, no-cost symposium for high school students to learn about potential careers in medicine, nursing, science, information technology, and business administration. The Health Careers Symposium will take place on Saturday, March 23, from 8:00 a.m. – 4:30 p.m. on Fox Chase Cancer Center’s main campus (333 Cottman Avenue, Philadelphia).

VIEW STORY